Park Ha Bio plans 1-for-50 reverse stock split

Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split of its Class A and Class B ordinary shares.

Accepted by SEC EDGAR 02/13/2026 - 04:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split of its Class A and Class B ordinary shares. The change has already been approved by shareholders and the board, and is expected to become effective on February 20, 2026, with trading beginning on a split-adjusted basis that day.

Immediately before the reverse split, the company has 104,768,362 ordinary shares issued and outstanding, reflecting its recent follow-on offering and related warrant exercises. After the reverse split, the share count is expected to be adjusted to 2,095,368 ordinary shares. Fractional shares will not be issued; any fractional amounts will be rounded up to the nearest whole share. The company does not anticipate other material changes to the terms of its securities in connection with this action.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse stock split did Park Ha Biological (BYAH) announce?

Park Ha Biological approved a 1-for-50 reverse stock split of its Class A and Class B ordinary shares. This consolidates every 50 existing shares into one new share, primarily changing the share count without altering overall shareholder ownership percentages.

When will Park Ha Biological (BYAH) reverse stock split take effect?

The reverse stock split is expected to become effective on February 20, 2026. Trading in Park Ha Biological’s ordinary shares is planned to begin on a split-adjusted basis at the market open on that same day, subject to Nasdaq Operations notice requirements.

How does the Park Ha Biological (BYAH) reverse split change share count?

Before the reverse split, Park Ha Biological has 104,768,362 ordinary shares issued and outstanding. After the 1-for-50 reverse split, this total is expected to adjust to 2,095,368 ordinary shares, significantly reducing the number of shares while keeping aggregate ownership proportionally the same.

How will Park Ha Biological (BYAH) handle fractional shares in the split?

No fractional shares will be issued in Park Ha Biological’s reverse split. Any shareholder position that would result in a fraction of a share will be rounded up to the nearest whole share, slightly increasing individual holdings in those specific cases.

Does the Park Ha Biological (BYAH) reverse split change security terms?

The company states it does not anticipate other material changes to the terms of its securities in connection with the reverse split. The primary change is the share consolidation and related adjustment in the number of issued and outstanding ordinary shares.

What events led to Park Ha Biological’s (BYAH) current share count?

The pre-split share count of 104,768,362 ordinary shares reflects two factors: a best-efforts follow-on public offering of units that closed on January 28, 2026, and subsequent cashless exercises of warrants that were issued as part of that offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File No. 001-42453

PARK HA BIOLOGICAL TECHNOLOGY CO., LTD.

(Translation of registrant’s name into English)

901, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒       Form 40-F ☐

Disclosure of Share Capital in Connection with Proposed Reverse Stock Split

Reference is made to the Form 6-K filed by Park Ha Biological Technology Co., Ltd. (the “Company”) on February 9, 2026, announcing the Company’s intention to effect a 1-for-50 reverse stock split (the “Reverse Split”) of its Class A and Class B ordinary shares, which has been approved and authorized by a majority of the shareholders at an extraordinary meeting of shareholders held on December 26, 2025, and the Board of Directors of the Company subsequently approved the reverse stock split and the exact ratio of the reverse stock split on January 29, 2026.

The Company is providing the following disclosure regarding its issued and outstanding share capital prior to and following the proposed Reverse Split.

Proposed Timing of the Reverse Split

Subject to the Company’s satisfaction of Nasdaq Operations notice requirements, the Company expects the Reverse Split to become effective on February 20, 2026, with trading to begin on a split-adjusted basis at the market open on that day.

Pre-Reverse Split Issued and Outstanding Share Capital

As of the date of this Report, and immediately prior to the effectiveness of the Reverse Split, the Company’s total issued and outstanding share capital consists of 104,768,362 ordinary shares, comprised of:

● 85,718,362 Class A ordinary shares (par value US$0.00002 each, with 1 vote per share); and

● 19,050,000 Class B ordinary shares (par value US$0.00002 each, with 20 votes per share).

This share count reflects the cumulative impact of (i) the Company’s best-efforts follow-on public offering of units, which closed on January 28, 2026, and (ii) subsequent cashless exercises of warrants issued in that offering.

Post-Reverse Split Issued and Outstanding Share Capital

Upon the effectiveness of the Reverse Split, the Company’s issued and outstanding share capital is expected to be adjusted to 2,095,368 ordinary shares, comprised of:

● 1,714,368 Class A ordinary shares (par value US$0.001 each, with 1 vote per share); and

● 381,000 Class B ordinary shares (par value US$0.001 each, with 20 votes per share).

No fractional shares will be issued in connection with the Reverse Split. All fractional shares resulting from the Reverse Split will be rounded up to the nearest whole share.

No other material changes to the terms of the Company’s securities are anticipated in connection with the Reverse Split.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 13, 2026

	Park Ha Biological Technology Co., Ltd.
	By:	/s/ Xiaoqiu Zhang
	Name:	Xiaoqiu Zhang
	Title:	Chief Executive Officer and Chairperson of the Board

2